NCT02578550View on ClinicalTrials.gov

A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Healthy

Interventions

DRUG

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)

A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.

DRUG

Emtricitabine/tenofovir alafenamide FDC

A single tablet containing FTC 200 mg and TAF 10 mg will be administered.

DRUG

Darunavir

A single tablet containing darunavir 800 mg will be administered.

DRUG

Cobicistat

A single table containing cobistat 150 mg will be administered.

Trial Locations (1)

Unknown

Groningen

All Listed Sponsors

lead

Janssen Sciences Ireland UC

INDUSTRY

NCT02578550 - A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants | Biotech Hunter | Biotech Hunter